Narchinol B exhibits anti-inflammatory and anti-neuroinflammatory effects by inhibiting the production of pro-inflammatory mediators, including prostaglandin E2 (PGE2), inducible nitric oxide synthase (iNOS), and cyclooxygenase-2 (COX-2) proteins, as well as pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α); it significantly suppresses LPS-induced excessive nitric oxide (NO) production in BV2 cells (IC50 = 2.43 μM).